Table 1 Baseline characteristics of the patients treated with UCBT (n = 80)

Age, median (range)

31 (17, 61)

Sex, n (%)

 Female

37 (46.3)

 Male

43 (53.7)

Diagnosis, n (%)

 AML

35 (43.8)

 ALL

20 (25.0)

 AA

13 (16.2)

 MDS

8 (10.0)

 Other

4 (5.0)

Disease status prior to transplantation, n (%)

 PR/NR

25 (31.3)

 CR

55 (68.7)

HLA compatibility (/10), n (%)

 ≤ 6

25 (31.3)

 7–8

44 (55.0)

 ≥ 9

11 (13.7)

Conditioning regimen, n (%)

 RIC

11 (13.8)

 MAC

69 (86.2)

ABO incompatibility, n (%)

 Identical

29 (36.3)

 Major

17 (21.3)

 Minor

23 (28.7)

 Bidirectional

11 (13.7)

 Infused TNC, (mean ± SD) × 10⁷/kg

2.79 ± 3.35

 Infused CD34⁺cells, (mean ± SD) × 10⁵/kg

1.81 ± 1.24

aGvHD, n (%)

 Grade 0–I

48 (60.0)

 Grade II–IV

32 (40.0)

CMV infection posttransplant, n (%)

 With

61 (76.3)

 Without

19 (23.7)

Pulmonary infection posttransplant, n (%)

 With

21 (26.3)

 Without

59 (73.7)

PES, n (%)

 With

51 (63.7)

 Without

29 (36.3)